Chantale Branson, MD
Sleep Medicine · Atlanta, GANPI 1538428826
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,000 of the $17,212 with a category attached, or 63.9%. 26 manufacturers reported payments, led by UCB SA at 54.6% of the total. 2025 is the largest year on record at $12,870, more than ten times the $29 reported in 2019. Among sleep medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $110.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$9K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Acadia Pharmaceuticals Inc$914
- MDD US Operations, LLC$575
- Teva Pharmaceuticals USA, Inc.$528
- plus $2K from 20 others
What the payments were for
- Consulting fees$11,00064%
- Speaking & faculty fees$5003%
- Food & beverage$5,68733%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 1 | $9,400 |
| AbbVie(2 entities) | 41 | $2,318 |
| Neurocrine Biosciences, Inc. | 20 | $1,336 |
| Acadia Pharmaceuticals Inc | 19 | $914 |
| MDD US Operations, LLC | 4 | $575 |
| Teva Pharmaceuticals USA, Inc. | 21 | $528 |
| AstraZeneca(2 entities) | 11 | $376 |
| EMD Serono, Inc. | 3 | $284 |
| Medtronic | 6 | $233 |
| Boston Scientific | 1 | $150 |
| Johnson & Johnson(2 entities) | 2 | $134 |
| Biogen | 2 | $119 |
| Kyowa Kirin, Inc. | 1 | $102 |
| Merz Pharmaceuticals, LLC | 2 | $101 |
| Amneal Pharmaceuticals LLC | 5 | $91 |
| Abbott | 2 | $84 |
| Supernus Pharmaceuticals, Inc. | 1 | $83 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Lilly USA, LLC | 4 | $70 |
| Argenx US, Inc. | 2 | $59 |
| Bristol Myers Squibb | 1 | $48 |
| Avion Pharmaceuticals | 2 | $29 |
| Viiv Healthcare Company | 1 | $25 |
| Harmony Biosciences LLC | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,212 in reported general payments places this provider in the 90th percentile of 50 sleep medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $209,595 |
| WakixPitolisant Hcl | 12 | $183,244 |
| Austedo XrDeutetrabenazine | 24 | $181,050 |
| NuplazidPimavanserin Tartrate | 22 | $110,306 |
| RytaryCarbidopa/Levodopa | 87 | $79,932 |
| Tetrabenazine | 23 | $17,395 |
| NeuproRotigotine | 11 | $12,221 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,450 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 50 | $2,397 |
| Pregabalin | 34 | $1,402 |
| Propranolol Hcl | 44 | $1,127 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 18 | $972 |
| Levetiracetam | 19 | $668 |
| Amitriptyline Hcl | 28 | $597 |
| Propranolol Hcl ErPropranolol Hcl | 16 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $528 | $390,64548 claims |
| Harmony Biosciences LLCWakix | $25 | $183,24412 claims |
| Acadia Pharmaceuticals IncNuplazid | $914 | $110,30622 claims |
| Amneal Pharmaceuticals LLCRytary | $91 | $79,93287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 sleep medicine providers in Georgia.
Other sleep medicine in Atlanta
- Murad AssaadAtlanta$139K
- Nancy CollopAtlanta$28K
- Scott LeibowitzAtlanta$22K
- Romy HoqueAtlanta$10K
- Jason YuAtlanta$3K
- Susan MuchaAtlanta$3K
- Abul MatinAtlanta$2K
- Paul ZoltyAtlanta$2K
- Samuel MickelsonAtlanta$1K
- Crystal CassimereAtlanta$631
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.